SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or ...

Sellas (NASDAQ:SLS) reported positive data from a Phase 2 study of its drug SLS009 in the treatment of patients with relapsed/refractory acute myeloid leukemia, or AML, with ASXL1 mutations.

SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia ... in patients with AML-myelodysplasia-related changes (AML-MRC) with ASXL1 mutation (cohort 4) and mutations ...

10 out of 14 patients (71%) had AML MRC (acute myeloid leukemia with myelodysplasia-related cytogenetics). 4 of those patients had myelomonocytic phenotype (M4 per FAB classification). The ...